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Abstract 
 
Coronary stents have changed the way in which coronary artery diseases are managed. 
Although bare-metal stents can be traced back to 1994, long term efficacy of these stents 
has been shattered by ISR (In-Stent restenosis)  and late stent thrombosis [1]. Research on 
finding a solution to these issues has led to the development of DESs (Drug eluting stents). 
However long term effectiveness of DESs and various drug delivery systems have raised 
concerns. Also current DESs does not have the capability to adjust the drug dose or release 
kinetics that corresponds to the diseased status of the affected vessel. Through the use of 
a drug delivery system which employs controlled drug release, it may be possible to 
control the release rate of the pharmacological drugs or substances of interest, and 
therefore one might be able to circumvent the range of events that leads to ISR, thus 
preventing the need for further invasive interventions [2]. To overcome the limitations of 
drug delivery systems, the administration of drugs using nanoparticle based microcapsules 
as carriers is being researched for their ability to facilitate a sustained, prolonged and 
controlled release of drugs. But still much research is needed to evaluate and fix issues 
relating toxicity, chemical and mechanical properties of the nanoparticles [3]. This project 
combines a range of nanobiotechnological techniques to synthesise nano-components 
which are finally assembled together to get the microcapsules which could be used in drug 
delivery systems. The microcapsules were engineered keeping in mind their potential use 
in an ultrasound based drug delivery system. 
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1. Introduction 
 
According to data published by the world health organisation (WHO), out of the total 57 
million deaths that occurred in the year 2008, 63% were due to non-communicable 
diseases (NCDs). A towering 48% (17 million) of these deaths due to NCDs were found 
to be due to cardiovascular diseases (CVDs), which is almost 30% of all global deaths [5]. 
And of these 17 million deaths, approximately 42.2% (7.3 million) were attributed to 
coronary heart disease (CHD) also known as coronary artery disease (CAD) [6]. Statistical 
data also suggest that the number of deaths due to CVDs is projected to reach an 
overwhelming 23.3 million by 2030 [7]. Therefore, the need to research and develop novel 
methods to treat this global problem is paramount. 
 
CHD, which is the most common CVD, is caused due the narrowing of the lumen of the 
arteries in the heart which occurs due to the build-up of plaque along the inner walls of 
the arteries, which causes reduced blood flow thus depriving the heart of oxygen and 
nutrients to the cardiac tissues. One of the main treatment of this narrowing of the arteries 
within the heart is by the placement of stents in the narrowed region to bring back the 
normal blood flow. But the main issue with this ‘stenting’ is the high rate of occurrence 
of in-stent-restenosis. In order to deal with this, drug eluting stents (DESs) are being 
developed and used. A DES is usually made up of three parts: the body of the stent which 
provides the structural support, the drug to be eluted and finally the drug carrier [8],  [9],  
[10].  
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The drug carrier in the stent is a significant component in DESs. The quality and the 
effectiveness of a DES directly depends on the drug carrier. They should meet a wide 
range of requirements before being able to be used in stents. The drug carrier (usually a 
polymer) should be biocompatible in order to prevent any inflammatory/rejection 
reactions. Also one should ideally be able to control the drug release therefore the 
concentration of the drug within the arterial wall can remain within the therapeutic 
window. This would enable the drug concentration to be high enough to hamper the 
proliferation of smooth muscle cells (SMCs) in a timely manner without causing any 
short/long-term effects which may adversely affect the arterial walls [11]. 
 
Recent developments in biomedical engineering have made the development of newer and 
better drug delivery systems for stents possible, especially in combination with advanced 
nanotechnological techniques. Novel drug delivery mechanisms which utilise drug 
encapsulation, followed by drug release through an external stimulus (e.g. ultrasound) 
which can be triggered once the encapsulated drug is at the site of interest has gained a lot 
of interest over the last years [12]. Clinical usage of these kinds of new novel drug delivery 
systems for treatment of in-stent restenosis are however in their early stages and this area 
of research needs further attention as the possibilities are vast. This project work therefore 
explores this area in an attempt to create a drug carrier which can be used in an advanced 
drug delivery system, preferably for a drug eluting stent and that which could be possibly 
used in a drug delivery system which employs ultrasound for drug release. 
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2. Aims and Objectives: 
 
The main aim of this thesis was to explore a new concept which would enable the 
development of novel drug delivery systems and contribute to research in the area. 
Utilising previous research in this area, this project experiments in creating a generic drug 
delivery capsule using recent nanotechnological processes and photophysical techniques. 
The objective was to obtain nano-assembled microcapsules which could be used in various 
drug delivery systems. The long term goal of the project was to use the obtained 
microcapsules embedded with gold nanoparticles in novel drug delivery systems. The 
ingenuousness of the method explored here is that if the process to make the microcapsule 
was to prove successful, the method could be used to get similar drug carriers which could 
be put into a wide range of uses. However, one of the chief motives of this experiment 
was to produce a system which could deliver drugs for the treatment of CHD, specifically 
for ISR. Another motive being the ability to control the elution of the drugs from the 
system through non-invasive means. Since ultrasound is non-invasive, future research 
which focusses on drug elution from these carriers using ultrasound would prove very 
beneficial to drug delivery research. By exploring previous and current research and 
incorporating innovative techniques, the design of an advanced drug delivery system 
would be possible. But such a drug delivery system would need advanced drug carriers 
which should be dynamic and efficient. This project strived to create such a drug carrier. 
The microcapsules obtained could also be coated onto DESs and thus provide 
cardiologists the world over with the ability to control drug release and one-day systemic 
drug administration could be a thing of the past. 
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3. Review of Literature 
 
Biomedical engineering has seen tremendous growth over the past decade. This growth 
has led to the design, development and research of novel medical devices and systems 
which has contributed much to the field of healthcare. However, next generation medical 
devices and systems are always in demand, and in order to further advance the quality and 
level of treatment that a patient can get, innovation in this area is a necessity. In order to 
design any medical system, one must be familiar with the disease etiology and also with 
the functioning of the components of the said system. The section below hopes to address 
the current clinical options, their limitations and the need for the development of a novel 
drug delivery system for use in CHD treatment. 
 
3.1 Coronary Heart Disease 
 
CHD is also known as coronary artery disease (CAD), atherosclerotic cardiovascular 
disease (ACD), atherosclerotic heart disease (AHD) or ischemic heart disease (IHD)  [13],  
[14],  [15],  [16],  [17]. CHD affects coronary circulation thereby directly affecting blood 
supply to the heart. Coronary arteries are the vessels which deliver blood that is rich in 
oxygen to the myocardium. But these arteries are susceptible to atherosclerosis. The 
process of atherosclerosis is not yet fully understood, however research has found that it 
is initiated due to inflammatory responses by the endothelial cells of the arterial walls in 
response to low density lipoprotein (LDL) particles [18]. The disease starts with the 
formation of fatty streaks which are made up of LDLs and white blood cell deposits (both 
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alive and dead cells) as seen in the image (Figure 1) below. This disease tends to progress 
very slowly, generally over decades and mostly remains asymptomatic until the 
accumulated atheroma breaks away, which may lead to a blood clot at the site of the 
atheroma rupture, or the ruptured atheroma may form a clot at a narrower region in the 
artery. The above events may lead to a complete blockage of blood flow which leads to 
ischaemia of the myocardium thereby triggering a myocardial infarction which can prove 
fatal [19]. 
 
 
Figure 1: Atherosclerosis; A) Healthy arteries. B) Initiation of atherosclerosis (Fatty 
streak). C) Plaque formation. D) Pathway to a clot [20]. 
Though there are a wide range of reasons which may lead to stenosis in the arteries, so far 
no one has been able to pinpoint any one causative process that is definitive. However 
recent research has been able to put together a range of processes such as thrombosis, 
inflammation, proliferation, remodelling which may precede the condition [21].  
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3.1.1 Treatments 
 
CHD treatments are usually dependent on the symptoms exhibited by the patient and the 
severity and/or the stage of the disease. Usually the treatment options for a CHD may be 
categorised into three types. 1) Through drugs 2)  Through coronary artery bypass grafting 
(CABG) 3) Through coronary interventions  [22].  Non-medical treatments such as 
lifestyle changes has also been proved to be effective in reducing the occurrence of CHD.  
For example, diet changes in some cases have even proved to reverse CHD [23]. 
Therefore, lifestyle changes are advised strongly for persons who are CHD prone and for 
patients who already have heart diseases. However, if one was to be diagnosed with CHD, 
lifestyle changes alone would not be enough and therefore suitable medical treatments are 
necessary to treat the problem. This medical treatment could however be assisted by 
positive lifestyle changes to aid in recovery and improved efficacy of the treatment. 
 
3.1.1.1 Treatment through Drugs 
 
Early stage atherosclerosis is usually treated through administering pharmaceutical drugs. 
The purpose of these drugs are to prevent further complications and to ease the symptoms 
for the patients. For example, statins can be used to reduce the amount to LDLs circulating 
in the blood; to prevent the reoccurrence of a myocardial infarction due to atherosclerosis, 
angiotensin converting enzyme (ACE) inhibitors and beta blockers can be used. Most of 
the time, a combination of drugs is used to treat the disease. Systemic drug administration 
is still one of the main ways used to treat atherosclerosis. 
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Pharmaceutical agents such as lipid-lowering drugs, anti-inflammatory drugs, antibiotics, 
antioxidants, antiproliferative drugs and other similar drugs hold good potential to alter 
the natural process of atherosclerosis. Drugs which interfere with the platelet-vessel 
interaction, inflammatory response, matrix production and proliferation of cells have also 
shown good results in vitro [24]. Angina can be managed using nitrates, calcium channel 
blockers can be used to reduce the heart rate and also to dilate the blood vessels  [25] while 
aspirin can be used to reduce clot formation tendencies. However, usage of drugs at a later 
stage of the disease can be ineffective at times and therefore invasive methods of treatment 
are needed. 
 
3.1.1.2 Treatment through CABG 
 
CABG is more effective than medical management through drug administration at 
relieving symptoms of CHD [26]. Usually CABG is carried out on patients who are at a 
higher risk to have a heart failure due to CHD. This is a type of arterial revascularization 
in which the coronary circulation to the myocardium is re-established by means of creating 
a connection which bypasses the blocked blood vessel which in this case would be an 
artery. The connecting vessel usually would be ideally taken from somewhere else from 
the patient’s body to maintain biocompatibility and to prevent graft rejection. This 
treatment was successfully introduced in 1960 by Robert H. Goetz who was a surgeon and 
his team [27]. This procedure has rapidly become a standard treatment for people with 
advanced stage CHDs over the years. 
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Modern technology has enabled the development and further improvements of minimally 
invasive CABG. Off pump coronary artery bypass (OPCAB) for example, is a technique 
of performing CABG without using CPB (Cardiopulmonary bypass - commonly known 
as the heart-lung machine) [28]. Newer innovations to OPCAB have resulted in a further 
minimal invasive treatment method known as minimally invasive direct coronary artery 
bypass surgery (MIDCAB) also known as a “keyhole” heart surgery which is a technique 
of performing CABG through an incision of 5-10cm size [29]. The incision is usually 
made between the ribs and entry to the chest cavity is gained by a minute thoracotomy. 
The treatment and recovery times of these newer methods are far less than the 
conventional CABG. 
 
3.1.1.3 Treatment through Coronary Interventions 
 
Percutaneous coronary intervention (PCI) also known as coronary angioplasty or balloon 
angioplasty is a non-surgical form of CHD treatment. PCI involves the insertion of a 
deflated balloon or a suitable device on a catheter through the femoral or radial artery to 
reach the site of blockage in the heart. To guide the catheter to the site of blockage, X-ray 
imaging techniques are used. Once at the site, the balloon is inflated to open up the block 
thereby restoring blood flow. When the balloon catheter is removed from the site of 
blockage, the lumen diameter would to be expanded, however due to elastic recoil, the 
risk of a blockage after the procedure became much evident. Also the occurrence of a 
restenosis after a certain amount of time, which resulted in the loss of the luminal area is 
still a cause for concern [30]. To address these issues, a coronary stent is introduced into 
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the blood vessel to keep it open after the procedure, the stents could be coated with drugs 
to inhibit restenosis. PCI in combination with stenting is preferred for non-severe stages 
of CHD [31]. PCI has also shown consistently its ability to reduce symptoms due to CHD 
and also to lessen cardiac ischemia [32]. 
 
3.2 Coronary Stents 
 
A coronary stent is a flexible mesh-tube like structure which is inserted by means of 
catheterisation into a coronary artery to keep it open. It is an arterial wall support structure 
which is designed to stay inside the artery [33]. Stents are widely used these days in PCI 
to either restore or maintain blood flow to the myocardium [34]. Stents can be broadly 
classified as inert (non-eluting) and drug eluting stents (DESs) [35]. At present most of 
PCI procedures are assisted by stenting. Stenting procedure follows similar steps as that 
of PCI. The stent is mounted in a catheter in a compact form and on reaching the site of 
the block, it is deployed. Usually deployment is done through means of balloon expansion. 
For over 20 years this stenting technique has been in use for treating CHD [36]. An image 
explaining stent deployment can be found in figure 2. 
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Figure 2: Stent deployment; A) Catheterization B) Balloon inflation  
C) Balloon deflation and stent deployment [37]. 
Studies show that stents have reduced the occurrence of restenosis after PCI treatments in 
comparison to treatments involving balloon angioplasty without stenting. This is achieved 
because the stent opposes elastic recoil and late remodelling of the artery [38],  [39]. Still, 
the excess neointimal hyperplasia inside the stent induces a restenosis in 10%-30% of the 
patients who are treated [40]. This in-stent restenosis (ISR) which is a local and chronic 
response is a major issue which affects the treatment of CHD. 
 
3.2.1 Coronary Stent Design 
 
There are a wide range of factors which should be taken into account while designing a 
stent for use in the coronary arteries. The foremost thing to consider is the biocompatibility 
of the material which is to be used for the stent construction. The material properties of 
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the stent also play a major role in the performance of the stents. Mechanical properties 
such as surface smoothness, corrosiveness, strength, elasticity, ductility, etc. are also vital. 
The degradation of the material due to corrosion inside the artery can lead to the leeching 
of metal ions which can be toxic and therefore can affect the arterial wall or the tissues 
nearby [41]. Some of the commonly used materials for the construction of metallic 
coronary stents are 316L SS, Pt-Ir alloys, Ta, Ti, Ni-Ti, and Co-Cr alloys. For 
biodegradable metallic coronary stents, pure Fe and Mg alloys are used commonly [42]. 
316L SS is the most commonly used material and it provides good mechanical properties. 
It is also corrosion resistant. Other unconventional materials used in the construction of 
stents include nitinol which is a shape memory alloy, platinum, etc.  
 
When the materials which are used have a high radial strength, the struts can be made 
thinner without compromising structural support. Poor radial strength materials lead to the 
struts of the stents being thicker. It is very important that the stent has enough radial 
strength to keep the vessel open without collapsing on itself. The flexibility of the stent 
enables it to be guided properly by the catheter without affecting the blood vessels. 
Usually the thinner a stent is, the more flexible it would be. 
 
When using bare metal stents, biocompatibility and hemocompatibility still remains a 
large issue. Thrombosis and neointimal hyperplasia were found to occur commonly over 
the stented area [43]. Therefore coating the surface area of the stent with other materials 
to change the surface properties without affecting the mechanical properties of the stents 
has become a common method to address the above issues [44],  [45]. Metallic coatings 
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are the most common coatings used in stents. Recent advances in coating stents have made 
it possible for the use of polymers. Polymers that are used for coating coronary stents can 
be categorised as non-biodegradable, biodegradable, copolymers and biopolymers. 
Although there are a wide range of polymers which can be used to coat stents a few such 
as Polyethylene terephthalate (PET) and a few forms of polylactide (PLA) have been 
proved successful [42]. Since a lot of research exists on the feasibility of using PLA for 
stent coatings, this project uses PLA as the core for the microcapsule, hoping that the 
previous research could justify the selection of PLA as the material of choice. 
 
3.2.2 In-Stent Restenosis 
 
Almost half of the population of the patients who have had bare metal stents implanted 
had faced the occurrence of stenosis within the stents [46]. ISR can be mainly attributed 
to viral neointimal proliferation. However recent studies show that neoatherosclerosis may 
also play a vital role in the pathophysiology of ISR [47]. ISR can usually be said to have 
occurred if the diameter of the recurrent stenosis is greater than 50% of the diameter of 
the stent or over the edges of the stent [48],  [49]. ISR can also be traced to stent fractures 
[50] and to injuries that occurs while stenting.  
 
The image (Figure 3) below graphically explains the various processes which occurs after 
a stent-induced arterial injury. Stent-induced arterial injury is one of the precurosors of 
ISR. 
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Figure 3: Initiation of ISR after stenting; I) Accumulation of platelet rich thrombus II) 
Arrival of monocytes at the site of inflammation III) Proliferation of SMCs and monocytes 
IV) Arterial shrinkage [51]. 
 
Administration of drugs like heparin, ACE inhibitors, nitric oxide donors, abciximab, 
hirudin, tranilast, angiopeptin in a systematic manner had shown good results in laboratory 
over animal studies for ISR treatment but have failed in clinical trials [52],  [53]. The 
above failure was probably due to the inefficient concentrations of the said drugs locally 
and also can be blamed partially on the poor knowledge of the pathophysiology of 
restenosis at the time. This problem is in the process of being addressed by coating stents 
with suitable pharmacological agents on the surface thereby inhibiting restenosis [54]. 
Early studies dating back to the 1990s which used polymer coated stents for the treatment 
and prevention of restenosis has shown positive results [55]– [57]. As previously 
mentioned, a range of oral therapeutics like ACE inhibitors, statins, calcium channel 
blockers (CCBs), vitamins, antiproliferative, antiplatelet and anticoagulant drugs have 
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also showed promising results. Out of these drugs, the most effective drugs at addressing 
ISR were found to aspirin and heparin which are antiplatelet and antithrombotic drugs 
respectively. Systematic administration of the said drugs decide whether the treatment is 
a success or not [58]. 
 
3.2.3 Drug Eluting Stents 
 
Even though stenting has reduced the occurrence of restenosis in comparison to treatment 
that includes balloon angioplasty alone, the very high rate of occurrence of ISR has led to 
increased interest in DESs. It is expected that DESs would be the route to solve the 
problem of ISR [59]. CHD treatment has been revolutionised over the past decade through 
the use of DESs [36]. Also the arrival of DESs has also not only reduced the occurrence 
of ISR, but has also made it possible to treat more complex lesions without the need of a 
much more invasive bypass surgery [21]. The need for usage of DESs can be attributed to 
the fact that oral drug administration does not have an effective impact on the rate of 
restenosis [60]. The main reason for the above maybe due to the inadequate concentrations 
of the drug at the stent site, which can be addressed through the use of DESs. DESs so far 
has had a huge effect on the rates of ISR; 30 to 40% of ISR occurrence in patients with 
BMS compared to 0-9% with patients with DES [61]– [64]. A strut of a typical drug 
eluting stent can be seen from the image (Figure 4) below. 
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Figure 4: Cross sectional view of the strut of a generic DES [65]. 
 
3.2.3.1 DES’ Drug Delivery Mechanisms 
 
The drugs in DESs can be released either by physical or chemical means. Physical means 
of altering drug elution rates are preferred over chemical release mechanisms because for 
the latter, the carrier would need to carry modified drugs which would result in extra 
chemical entities [66]. The mechanisms of drug release can be further classified into five 
systems viz. Diffusion system, degradation system, ion exchange system, osmosis system 
and prodrug system. Diffusion and degradation systems can be differentiated into 
reservoir and matrix sub systems [66]. This thesis aims to combine a few of the above 
systems into one in an attempt create a novel mechanism for drug delivery. 
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3.2.3.2  Limitations of DES 
 
Technologically DES are far more advanced than bare metal stents, however DESs do 
have limitations that need to be addressed. Many DES studies which show promising 
results do not take into account many complex real world lesions. Also the results of 
studies which included more complicated lesions suggest that even though occurrence of 
ISR might have been reduced, they have not been completely eradicated [67]– [69]. For 
most of the DESs, studies show that the rate of drug release over the first few days of stent 
implantation is very high and hence most of the elution happens within that period while 
in some cases drug retention within the coating is also a cause for concern [70]. Therefore, 
it is highly necessary to create a delivery system where the drug release can be controlled. 
 
The other major limitation is the injury due to the stent itself. When any stent is placed in 
an artery, the chances of damage to the endothelial layer is almost certain. When the 
endothelial layer is affected, ISR could be initiated as a result of the various inflammatory 
responses. ISR can be observed in BMS more easily because the onset is early, however 
in DES the detection can be late as the onset of ISR delayed which is a problem [71]. Late 
stent thrombosis is another major issue that haunts DESs. Late stent thrombosis is the 
formation of a clot at the stent site which can cause the artery to occlude in the longer run. 
Late stent thrombosis as the name suggests does not occur immediately but rather years 
after the stent has been implanted. This makes the situation complex in case of old patients 
who would have aged further when this complication arises, thus making further 
treatments tricky.  In order to overcome these limitations, designing a drug delivery 
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system which can elute and retain drugs as and when required while remaining stable 
within one’s body over the years is imperative. 
 
3.3 Modern Drug Delivery Systems 
 
Recent technological advances have led to the engineering of better drug delivery systems. 
The use of nanotechnological techniques in biomedical engineering has led to a wide 
range of innovations which include better drug delivery systems [72]. Nanotechnology in 
this aspect includes the production and assembly of substances at the nanoscale including 
characterization and analysis using devices and also encompasses nanobiotechnology 
[73]. Nanomedicine in the present day has given rise to advanced drug delivery techniques 
[74]. Drug encapsulation in the nanoscale which aims to improve the efficacy, 
biodistribution, bioavailability of the drug while minimising the problems with drug 
concentration that are common in systemic drug administration, is one of the most 
promising areas in nanotechnology in modern times which offers much potential [75]. The 
figure 5 below represents diagrammatically some of the commonly used drug carriers.   
 
Figure 5: Various novel nanocarriers [76]. 
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Encapsulating drugs by means of nanocapsules as visualised in the figure above or using 
microcapsules and using them for drug delivery has become an exciting area to research 
because of the various possibilities it has to offer. Liposomes, nanospheres, nanocapsules, 
polymer conjugates, nanotubes, cells and various nanoparticles have shown the abilities 
to be used as nanocarriers. Microencapsulation offers protection for the encapsulated drug, 
makes it possible to control the drug release, makes it easier to administer the drug and 
finally provides one with the ability to pre-programme release profiles to match the needs 
[77]. Also the capsules have the potential to be engineered in such a way as to respond to 
stimuli such as pH, ultrasound, temperature, specific chemicals and radiation [78]. 
 
3.3.1 PE Microcapsules 
 
One of the ideal encapsulation methods is through the use of poly electrolyte (PE) 
microcapsules. Although they are termed as capsules, they are not capsules per se, but 
rather dispersed solid matrices lacking a definitive external wall phase. PEs are polymeric 
molecules which are obtained from ionisable monomers. PEs are also charged when 
suspended in an aqueous phase. PE microcapsules are made by coating differently charged 
PEs in alternative layers. PEs could also be used to coat colloidal particles which makes 
them suitable for use in a drug delivery system [12]. Maximum sizes of PE microcapsules 
can reach around 2000 micrometres depending on the layer thickness and the number or 
layer coatings. One advantage of using PEs is being able to modify the permeability of 
the capsule layer [79], thereby drug release and elution can be controlled. In PE 
microcapsules, another advantage is the possibility of being able to coat the drugs between 
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the layers instead of just encapsulation, this enables the usage of multiple drug layers and 
provides sustained drug release scenarios [80]. One of the most efficient processes of 
synthesis of microcapsule is through layer by layer assembly. This is achieved through the 
use of poly cations and poly anions. The most common poly cation - poly anion pair, PAH 
(Polyallylamine hydrochloride) and PSS (Polystyrene sulfonate) has proved to be among 
the best combination for creating PE microcapsules [78]. This layer by layer assembly is 
attained by coating one charged PE layer above the other PE layer that holds the opposite 
charge. This layering can be done as required [72]. 
 
3.3.2 Gold Nanoparticles 
 
Embedding gold nanoparticles on the PE layers of the microcapsule would provide a lot 
of desired properties to be added to the microcapsule which aid in optimal drug delivery. 
The sensitivity of the microcapsules would also be considerably increased and therefore 
the use of any stimuli to trigger drug release would be made comparatively easier [78]. 
Also unwanted retention of drugs within the capsules could also be lowered significantly 
when microcapsules embedded with gold nanoparticle use a stimuli based release system 
like ultrasound [12]. In addition to these,  gold is inert and non-toxic which further makes 
it a preferred material of choice [81]. Moreover, the gold nanoparticles play a role in 
improving the mechanical properties of the microcapsules by providing it with stability 
[82].  
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4.Materials and methods 
 
4.1 Introduction 
 
The experimental methodology of this project aims to show the potential that 
nanobiotechnology has to offer for the creation of a new drug delivery system. In the 
history of drug delivery systems, microcapsules that are loaded with drugs have been used 
for a wide range of therapeutic purposes. The following experiment researches the 
possibility and feasibility of using PLA (Polylactide) nanoparticles, gold nanoparticles 
and certain polymers (PEs) to create a novel drug delivery system. The main idea was to 
create a generic drug carrier which would be able to encapsulate drugs of interest to treat 
CHD. The intention was to dope a nanoparticle core which was made of PLA with 
Rhodamine 6G dye. Rhodamine 6G was used as a substitute in place of the pharmaceutical 
drug that has anti-ISR properties. Also Rhodamine has a range of photophysical properties 
and hence photophysical measurements could also be taken. Thus the PLA core infused 
with Rhodamine 6G would be made to undergo a multiple layering process, using 
alternative charges through employing Polyallylamine hydrochloride (PAH) and 
Polystyrene sulfonate (PSS) thereby encapsulating the PLA core and forming 
microcapsules. Therefore, the PLA core would be first coated with a layer of PAH, 
followed by a layer of PSS. The third layer would be coated using gold nanoparticles and 
finally another layer of PAH can be used to form another layer. Figure 6 clearly represents 
the coating process visually. 
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Since the layering is based on charge difference, the final layer attains a negative charge 
in our case because of the gold nanospheres. This offers us the possibility to coat it on 
stents by positively charging the stent strut.  
 
Figure 6: Diagrammatic representation of the layering procedure (Not to scale). 
 
4.2 Polylactide  
 
Polylactide is an aliphatic polyester which is also a biocompatible thermoplastic and has 
the potential to be used for controlled drug releases [83]. It is also biodegradable and 
lipophilic and has been used extensively in the biomedical field [84]. Figure 7 shows the 
structure of DL-Lactic acid. 
 
Figure 7: 2-D chemical structure of DL-Lactic acid. 
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The extensive use of PLA in the field of biomedical engineering can be attributed to its 
good mechanical properties and also to its ability to degrade both in vivo and in vitro to 
non-toxic products [85]. PLA is also nontoxic inside the human system which furthermore 
makes it suitable for use in several medical applications [86]. 
 
4.3 Polyallylamine Hydrochloride and Polystyrene Sulfonate 
  
PAH is a cationic polyelectrolyte (PE) obtained through the polymerization of allylamine. 
PSS is an anionic polyelectrolyte derived from polystyrene. The above polymers can be 
combined together to form layer-by-layer adsorbed films of negative-positive charges 
polymers [87]. The most prominent biomedical application of the above polymers is in 
the field of encapsulation. The capsule of layered PEs has very good structural integrity 
and has the potential to be used for drug delivery purposes [88]. 
 
4.4 Rhodamine 6G 
 
Rhodamine 6G (Rh6G) is a highly fluorescent dye. It is derived from xanthene and is 
frequently used an active medium and probe for photophysical analyses [89]. Rh6G is an 
ideal probe to be used because of its high light absorption and fluorescence properties 
[90],  [91]. In this experiment Rh6G is used generically in the place of a drug as a 
substitute, because of its property to be monitored easily through photophysical means. 
The chemical structure of the dye is shown in the figure 8 below. 
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Figure 8: 2-D chemical structure of Rhodamine 6G. 
Also Rh6G in combination with the biodegradable PLA can mimic certain characteristics 
of the real drug but also present one with the ability to monitor its elution. However, Rh6G 
cannot be used in real life trials or treatment because it is toxic and maybe even 
carcinogenic for humans. 
 
4.5 Gold Nanoparticles 
 
Gold nanoparticles have the ability to act as non-toxic nanocarriers which can be used for 
drug delivery applications. The gold nanoparticles provide stability to the capsule and the 
layer also allows surface properties such as hydrophobicity and charge variations.  Also 
gold nanoparticles interact with thiols, thus enabling an effective and selective use for 
controlled intracellular release [82]. Recent research has made gold nanoparticles as an 
attractive tool for use in drug delivery systems [92],  [93].  
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4.6 Layering Process 
 
Assembly of the microcapsule will begin by taking the core doped with Rh6G which is 
negatively charged and coating it with positively charged PAH followed by negatively 
charged PSS followed by a second layer of PAH. The PAH and PSS combination is one 
of the most commonly used layering PE combo. Once the second PAH layer is complete, 
negatively charged gold nanoparticles would be used to form a layer above the positive 
charged PAH layer. The layering process can be done as many times as required to get the 
preferred number of layers. Many studies have been made to determine the ideal number 
of layers, however there is a lot more work needed to come to a solid conclusion on how 
the layers may affect the various characteristics of a microcapsule. In our case, the layering 
process is kept to a minimum; three PE layers followed by a gold nanosphere layer. 
 
One of the important things that needs to be correctly achieved in the layering process is 
to give the particles between each layer the proper temperature and proper mixing time to 
get a stable layer. Though the PE layer coatings did not need any change in temperature, 
for embedding the gold nanoparticles in the final layer, the PE coated PLA particles were 
exposed to boiling temperatures. The concentration of the surfactant was another 
parameter that needed attention. It should be noted that at one point in the experiment a 
high concentration of citrate was added due to a calculation error and it was not possible 
to synthesise any gold nanoparticles at all. Concentration of citrate was crucial factor in 
synthesis. The sizes of the nano-components should also be optimal for the layering to 
succeed. 
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4.7 Syntheses 
 
There were two main nano-components which were needed to be synthesised before they 
could be assembled; The PLA-Rh6G nanoparticles which were to be used as the core and 
the gold nanospheres which were to be embedded on the final layer of the microcapsule. 
 
4.7.1 Synthesis of PLA-Rh6G Nanoparticles 
 
4.7.1.1 Chemicals 
• Poly(D,L-lactide)  [PDLA (A form of PLA), ((C6H8O4)n), ester terminated, 
Mw=10,000-18,000], Sigma Aldrich [94] 
• Acetone (CHROMASOLV®) [(CH3COCH3), Mw=58.08], Sigma Aldrich 
• Rhodamine 6G [C28H31N2O3Cl, Mw=479.01], Sigma Aldrich 
• Distilled water 
4.7.1.2 Instruments 
• Analytical balance (Model: KERN ABT 120-5DM) 
• Hotplate and stirrer (Model: Jenway 1000) 
• Microfuge (Model: Sigma 1-14) 
• Ultrasonic bath (Model: Fischer FB15051) 
• Magnetic stirrer bars, centrifuge tubes, micropipettes, beakers, etc. 
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4.7.1.3 Method 
The synthesis of the PLA core was carried out according to previous published research 
work [95] [96]. The infusion of Rh6G with the synthesized PLA core was also carried out 
according to published research, where Rh6G is added to the acetone phase of the 
synthesis process [97]. This is because Rh6G is lipophilic. The process was as mentioned 
below. 
3.33 ml (ideal acetone-water ratio) of acetone was pipetted into a beaker. 5 mg of PDLA 
was then measured using the balance and added to the acetone solution. The solution was 
gently agitated to facilitate the dissolving of the PDLA. Now 0.1 mg of Rh6G was 
carefully measured and added to the above solution. The colour change of the colourless 
solution to an orange red colour due to the Rh6G dye was visualised. A magnetic stir bar 
was then added to the solution and the solution was placed on the stirrer for 1 to 2 hours 
to enable the Rh6G and PLA to attach. Once the stirring was over, the solution was 
pipetted out into 8.33 ml of distilled water under moderate stirring drop by drop. This is 
the aqueous phase.  
Once the above process was complete, the solution was transferred into 1ml centrifuge 
tubes and centrifuged for 30 minutes at 4,500 rpm followed by 10 minutes at 10,000 rpm. 
The supernatant was taken and kept aside for photophysical analyses and the polymer 
pellets infused with Rh6G were transferred to 10 ml of distilled water and ultrasonicated 
to enable suspension in the water. This made the PLA-Rh6G particles to get suspended in 
the solution which was later used as the core of the microcapsules to be assembled. 
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4.7.2 Synthesis of Gold Nanospheres 
4.7.2.1 Chemicals 
• Gold(III) chloride trihydrate [(HAuCl4 · 3H2O), Mw=393.83, 25mM] 
• Sodium citrate dihydrate [(HOC(COONa)(CH2COONa)2 · 2H2O), Mw=294.10 
• Distilled water 
4.7.2.2 Instruments 
• Analytical balance (Model: KERN ABT 120-5DM) 
• Hotplate and stirrer (Model: Jenway 1000) 
• Ultrasonic bath (Model: Fischer FB15051) 
• Magnetic stirrer bars, micropipettes, beakers, etc. 
4.7.2.3 Method 
To synthesise the gold nanospheres for use as nanoparticles in the experiment, the 
established method to form citrate stabilized gold nanoparticles [98] was followed. It was 
necessary that the nanoparticles which were synthesised would be nanospheres as the 
shape was vital to the success of the delivery system and also essential for the coating 
mechanism that was to be employed. 
150 ml of distilled water was pipetted into a beaker. 0.034 g of sodium citrate dihydrate 
was measured and added to the beaker. The beaker was then covered to prevent 
evaporation and the contents were dissolved by ultrasonication by placing it in the 
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ultrasonic bath for 2 to 3 minutes. To further dissolve the mixture, the beaker was placed 
on the hotplate and was brought to boil under stirring. Once the solution started to boil, 
1ml of 25 mM gold chloride trihydrate was pipetted into the solution while it was being 
stirred. The solution was then taken off the stirrer. The colourless solution undergoes 
colour changes until it finally becomes ruby red after cooling down. This significant and 
characteristic colour change marked the success of the gold nanosphere synthesis as the 
colour matched the absorption spectrum of the nanoparticles of this size range. The size 
of the nanospheres obtained through this process was approximately 10 nm and their 
concentration in the solution was around 3 x 1012 nanoparticles per ml. The charge of the 
nanospheres was negative because of the citrate ions. 
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4.7.3 Layer by Layer Assembly 
4.7.3.1 Chemicals 
• Poly (allylamine hydrochloride) solution (1g/l) 
• Poly (styrene sulfonic acid sodium salt) solution (1g/l) 
• Distilled water 
• Citrate stabilised gold nanoparticles (nanospheres) 
4.7.3.2 Instruments 
• Analytical balance (Model: KERN ABT 120-5DM) 
• Hotplate and stirrer (Model: Jenway 1000) 
• Microfuge (Model: Sigma 1-14) 
• Ultrasonic bath (Model: Fischer FB15051) 
• Magnetic stirrer bars, centrifuge tubes, micropipettes, beakers, etc. 
4.7.3.3 Method 
The PLA-Rh6G particles which were earlier synthesised and suspended in distilled water 
were now used for the assembly of the microcapsules. At each stage in the process, the 
supernatant was kept for photophysical analyses. The layering was carried out in a ratio 
of 1:1. The PLA-Rh6G was earlier suspended in 10ml of distilled water. This 10 ml was 
further concentrated to 5 ml through centrifugation and resuspension. After this, 5 ml of 
the PAH solution was added to the above and placed on the stirrer for 2 hours. The solution 
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was then centrifuged for 30 minutes at 14000 rpm. After centrifugation the particles were 
separated and resuspended in 5 ml of distilled water through ultrasonication. After 
resuspension, 5 ml of PSS was added to the above and then placed on the stirrer for 2 
hours. After the stirring process, the solution was centrifuged as before and the pellet 
resuspended in 5 ml of distilled water. A second PAH layer was then formed over the 
above PSS layer using the above method. And finally 2 ml of the gold nanosphere solution 
was added to the solution which had suspended particles of PLA coated with PAH-PSS-
PAH. Again the solution was placed on the stirrer for 2 hours, followed by centrifugation 
and finally resuspension. This solution would have the microcapsules with gold 
nanospheres as the outermost layer. Another layer of PAH over the gold layer followed 
by PSS can also be produced. The ingenuity of this method is that the number of layers 
can be varied as required. 
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4.8 Photophysical Analyses 
4.8.1 Instruments 
• V-660 Research UV-Visible Spectrophotometer by Jasco 
• FluoroLog®-3 Spectrofluorometer by Horiba Scientific 
4.8.2 Software 
• FluorEssence™ for Windows® by Horiba Scientific  
• SpecWin Pro 
• OriginPro™ by OriginLab® 
• Microsoft® Excel 
4.8.3 Method 
Photophysical analysis of the samples were carried out at the synthesis of each and every 
nano-components and also during each layering step. The Rh6G which was infused with 
the PLA core was crucial to the measurements obtained. The solutions to be analysed 
where placed in cuvettes and either placed in the fluorometer for emission analysis or the 
spectrometer as per the requirements. The absorbance range used between 300 to 800 nm 
because Rh6G usually has an excitation peak around 520-530 nm and this range matched 
with that of Rh6G. Suitable software were used to operate the instruments and to interpret 
the data obtained. The findings were plotted as graphs and were analysed. 
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4.9 SEM Analysis 
4.9.1 Chemicals 
• Final solution containing microcapsules 
4.9.2 Instruments 
• Hitachi Tabletop Microscope TM-1000 
4.9.3 Method 
For the sample to be analysed using SEM, the sample needs to be dry and therefore the 
solutions obtained in our experiment could not be used directly as such. To observe the 
samples in the SEM, the samples were agitated to make sure that the particles were well 
suspended, after which a drop of the sample was placed on a small glass slide and dried 
thoroughly naturally. The sample after the layer by layer assembly process was then 
prepared for SEM by following the above steps. Though the drying method of the sample 
was crude, there seemed to be no other alternate way to observe the sample in its liquid 
condition microscopically. When the sample was observed under the microscope 
however, there seemed to be no drastic effect of the drying process on the particles as clear 
images of the synthesised particles were seen. However, the effect the drying process may 
have had on the characteristics of the particles is unknown. 
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5. Results and Discussion 
5.1 Photophysical Analyses 
Absorption and emission spectra are central to photophysical analyses. To obtain a clear 
understanding of the analytical methods, the fundamentals must be well understood 
beforehand. Rh6G used in this experiment is a fluorophore. Fluorophores are 
photochemicals which reemit light when they are excited. Every fluorophore exhibits a 
unique and a characteristic adsorption/emission spectrum. 
Absorbance measurements provide one with the wavelengths of the light which are 
absorbed by the substance. The absorption by the substance is because of the photon 
causing the electrons in the substance to get to an excited state. This causes a state of 
energy gain and this lasts only for a very few nanoseconds.  It can also be said that the 
absorption spectra would correspond to the fluorescence emission spectra to a certain 
degree when approximated. 
Fluorescence emission reading is dependent on the intensity as the absorbance reading. 
Once the substance after being hit by light returns to ground state, photon emission takes 
place. This causes a state of energy loss and this is usually in the form of vibrations. The 
light emitted here would be of lower energy when compared with that of the absorbed 
beam and also would have a higher wavelength. 
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Figure 9: Normalised absorption spectra and emission spectra of Rh6G  
(Stokes’ shift of around 25nm cab be observed). 
Stokes’ shift, which is the difference between the peak maxima of the absorbance and 
emission wavelengths plays a major role in the experiment. In the experiment, from the 
Stokes’ shift one can infer if the excitation is due to the light emitted or due to the light 
used to excite the substance. Stokes’ shift is also the reason why the emission spectra have 
proportionally higher wavelengths to that of the absorbance spectra as seen from the graph 
(Figure 9) above.  
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5.1.1 Photophysical Analysis during PLA-Rh6G synthesis 
 
During every step of the synthesis of particles, photophysical analysis was carried out to 
confirm that the process was going on as intended. The mixing of Rh6G with the PLA 
could be observed visually by the colour of the pellets as seen in figure 10. PLA on its 
own is colour less or white, but the pellets below exhibit the distinct shade of orange-red 
corresponding to the Rh6G dye and therefore it could be confirmed that the Rh6G has 
indeed adhered to the PLA. 
 
 
Figure 10: Centrifuge tubes showing the PLA-Rh6G pellets. 
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After the synthesis of the PLA-Rh6G particles, the supernatant was analysed. The 
following graph (Figure 11) was obtained through photophysical analysis. 
 
 
Figure 11: Emission and absorbance spectra of PLA-Rh6G Supernatant. 
 
The absorbance values of the graph clearly correspond to that of the absorbance values of 
the Rh6G dye. A wavelength range suiting Rh6G which is between 300 and 700 nm was 
used. The peak of the absorbance as seen from the graph was around 525 nm. The 
absorbance values in the graph above correspond directly and proportionally with the 
intensity of colour of the supernatant solution, i.e. if the concentration of the Rh6G in the 
solution was increased, the colour intensity would be higher thereby producing higher 
absorbance values. For the supernatant in this case, at the peak of 530 nm, an absorbance 
value of 3.40 was obtained. Going below 340 nm wavelengths, the fluctuation of the signal 
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occurs as the spectral region falls outside the range of the Rh6G dye as seen in the graph 
(Figure 11) above. 
 
The emission spectra for Rh6G was measured from around 550nm to 800nm which is the 
ideal range. The peak of emission was found to be around a wavelength of 566nm. The 
emission intensity was deduced to be around 2 x 108. To find the Stokes’ shift the 
difference between the wavelength peak maxima which on our case is 566-530 which 
gives us a value of 36 nm. 
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After the analysis of the supernatant, the sample containing the suspended Rh6G was then 
analysed as carried out previously. The following graph (Figure 12) was obtained when 
the data were plotted.  
 
 
Figure 12: Emission and absorption spectra of sample containing PLA-Rh6G particles. 
 
In this case, the absorbance maxima were at 528 nm and the emission peak was at 554 
nm. Therefore, the Stokes’ shift was 554-528 = 28 nm. The Stokes’ shift here is lower 
than the 36 nm observed previously for the supernatant. Since the Stokes’ shift is smaller 
a bigger overlap between the emission and absorbance spectra can be visualised. The 
absorbance at the peak was 0.169 nm approximately, while emission max was around 3.43 
x 106. 
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5.1.2 Photophysical Analysis during Gold Nanoparticle Synthesis 
 
The success of the procedure for gold nanospheres was marked by the characteristic colour 
of the solution obtained as seen below. The ruby red colour of the solution is due to the 
fact that the solution absorbs blue and green colours which is due to the plasmonic optical 
properties of the gold nanospheres. This causes the solution to emit red light which could 
be observed clearly. 
 
From the spectral graph below, it could be further proven that the colour change 
corresponds to the nanoparticles of relative size of approximately 10nm as the graph 
below (Figure 13) suggests the absorption of green and blue photons at the peak which is 
around 530 nm. 
 
Figure 13: Absorption spectrum of gold nanoparticles (13 nm) [99]. 
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Once the gold nanospheres were synthesised, the solution was analysed and the following 
spectral graph (Figure 14) was obtained for absorbance. 
 
  
Figure 14: Absorption spectra of gold nanospheres solution. 
The above graph displays the characteristic shape for gold nanospheres, which further 
supports that gold nanospheres were indeed successfully synthesised. The absorbance 
peak maxima occur at a wavelength of 524 nm marked by an absorbance of 0.717. This 
peak corresponds with the nanoparticles sized between 10 nm to 13 nm which further is 
in line with the intended requirement of approximately 10 nm. It can also be noted that 
this absorption graph corresponds with the spectral graph for the gold nanoparticles seen 
earlier. 
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
300 350 400 450 500 550 600 650 700 750 800
A
bs
or
ba
nc
e (
A
U
) 
Wavelength (nm)
Absorption spectra of gold nanospheres 
solution
   41 
 
5.1.3 Photophysical Analysis during Layer by Layer Assembly Process 
5.1.3.1 Absorbance Measurements 
 
Throughout the entire layer by layer assembly process, the supernatant at each step was 
kept aside and photophysically analysed. Absorbance measurements were taken to ensure 
that the Rh6G was at a minimum during each stage. Less leakage of Rh6G would mean 
less drug loss in the real drug delivery scenario. 
 
 
Figure 15: Absorption spectra of the supernatant throughout the layering process 
 
The absorbance range was again set in favour of Rh6G which was within 400 to 700 nm. 
When the first PAH layering had been achieved, the supernatant was found to have an 
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absorbance peak at the wavelength of 525 nm with an absorbance value of 0.0455. The 
shape of the curve seems to correspond with that of the PLA-Rh6G supernatant and this 
is understandable because of the possibility of the presence of Rh6G in the supernatant, 
since it is the first layer. Over the second and third layers, it can be seen that the detection 
of Rh6G seems to have significantly declined. 
 
When the sample containing the product with the gold nanoparticles was analysed, the 
level of absorbance had increased and a significant shift in absorbance could be seen as in 
the graph above. This suggests the presence of the gold nanospheres in the top layer, and 
hence the huge rise in absorbance. The overall graphical data (Figure 15) support the fact 
of the presence of new particles in each layering step thereby indirectly supporting the 
synthesis of new materials. 
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5.1.3.2 Emission Measurements 
 
The fluorescence emission spectra of the supernatant were similarly obtained and the data 
were plotted (Figure 16). The values were adjusted proportionally to be able to fit into a 
single graph thus enabling a comparative understanding. 
 
 
 
Figure 16: Emission Spectra of the supernatant throughout the layering process 
The emission peaks for the first three layers were significantly visible in comparison to 
the absorbance values, where a detectible peak was only observed for the first layer. For 
the supernatant of the PLA-Rh6G-PAH particles the peak maximum occurs at around    
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551 nm. For the first PSS layer, peak max was recorded at 558 nm followed by a peak 
max of 550 nm for the second PAH layer. Once the gold nanosphere layer was formed, 
the emission curve almost flat lines with a peak max at a wavelength of 561 nm. Since the 
range of the peak maxima of all these supernatant remained very close, it can be inferred 
that the supernatant at the final steps did not have any considerable particles. This shows 
the efficiency of the layering process. Also it can be clearly deduced that the concentration 
level of Rh6G started to significantly decrease in every layering step, thus showing that 
the leakage of Rh6G has almost come to a halt and proving that each layer adds additional 
stability to the core. This finding is also in correlation with similar published studies [100]. 
The emission graph above together with the absorbance graph could be used to further 
support the efficacy of the methods that are used for the synthesis. Clear and distinct shifts 
between each process could be observed on the graphs which could therefore substantiate 
the claims that the syntheses and layering processes were efficient in the creation and the 
assembly of the layers. 
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5.2 SEM Analysis of the Final Microcapsules 
 
After the final layering of the microcapsule, the solution was visualised under an SEM. 
Clear individual microcapsules were observed. The sizes of the obtained particles had an 
overall mean size of 0.3795 µm which is 379.5 nm with a standard deviation of 0.2475 
µm which is 247.5 nm. Though the sizes vary slightly, the distribution seems to be 
consistent which shows that they are equally distributed throughout the solution and well 
suspended. The SEM images (Figure 17) coupled with the Spectroscopic data can be used 
to prove the success of synthesising the intended microcapsules. 
Figure 17: SEM images of the final PE microcapsules with the gold nanosphere layer. 
The two images at the top show magnifications at 2500x and 5000x each, while the 
bottom two shows a magnification of 10000x each. 
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The images at x10k magnification were analysed using ImageJ (Figure 18) 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
The SEM data was then analysed further using excel and the above size distribution 
histogram (Figure 19) was obtained. The distribution of the sizes of the particles could be 
visualised graphically from this image. The number of particles corresponding to each 
sizes could be observed from the histogram above. From the histogram it could also be 
Figure 19: Particle size distribution histogram (All units are in nm). 
Figure 18: ImageJ analysis of nanoparticles (All units are in µm). 
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inferred that the particles are normally distributed. Future research should concentrate on 
the shapes and sizes of the particles. This would enable synthesis of particles which are of 
uniform dimensions and are distributed evenly. 
 
A cause for concern was the observational process itself. Since the SEM could not be used 
to observe liquid samples, the sample obtained in our case had to be dried out. Therefore, 
it is necessary to know how the drying process could have affected the properties if the 
synthesised materials. The intended particles were expected to be spherical entities; the 
slightly irregular shapes could be blamed partially on the method of drying of the sample.  
 
The clumping of the nanoparticles as observed in the SEM images could be also caused 
due to the crude drying procedure. Also since the nanoparticles have not been attached to 
any surface, the clumping is inevitable. However, when these nanoparticles are coated on 
to stents one does not need to be concerned about the clumping of the nanoparticles since 
they would be attached to the stents and would not be mobile thus the chances of these 
particles clumping together would be significantly reduced.  
 
In future projects, the improvements on the imaging techniques could be further worked 
upon. Different imaging techniques such as transmission electron and atomic force 
microscopy could be explored to obtain better images. Also the microcapsules could be 
coated onto metal like gold or titanium sheets before imaging, which would enable the 
optimal distribution of the particles and prevent them from clumping and also from being 
distributed unevenly as observed here. 
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5.3 Final concept 
 
The ultimate goal of the project was to create microcapsules which could later be coated 
onto stents and then eluted using novel mechanisms. The microcapsules had been obtained 
successfully, however further research needs to be done with regards to coating them onto 
stents. 
 
Figure 20: Proposed use of the obtained microcapsules in stents (Illustration only, not to 
scale) 
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As the picture above (Figure 20) explains, the microcapsules that were obtained could be 
coated onto stents. Theoretically, the coating could be done based on charge difference, 
which would mean that the stent strut would have to be charged oppositely to that of the 
final layer of the microcapsules. The microcapsules would then be needed to be loaded 
with drugs before coating it onto the stents. This can be done wither through removing the 
core by degrading it or by creating the capsule using the drug as the core itself. This would 
depend on the properties of the drug itself. If the drug is not stable enough mechanically, 
it would not be possible to coat layers over the said drug and in that case, using an alternate 
core would be followed. Once coated onto the strut of the stents, various release 
mechanisms could be explored. But the release mechanism of interest in our project was 
the use of ultrasound to elute the drugs. This could be explored in future projects to test 
whether the microcapsules which were created are suitable for an ultrasound triggered 
release system or not. 
 
The obtained microcapsules can be used for a wide range of various purposes, the chief 
one being carriers for drugs. The stability and other properties of these kinds of 
microcapsule have been previously studied, and also the characteristics of these capsules 
with relation to temperature differences and materials used were studied extensively [101].  
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6.Future Research Possibilities 
 
The experimental goal of the project was to synthesise novel microcapsules which could 
be used in drug delivery systems, but primarily on DESs. Studies have been carried out 
with regards to loading ISR treatment drugs like paclitaxel onto the shell of microcapsules. 
These studies found a method to control the drug concentrations in the capsule by varying 
the number of layers of the capsules [102]. The same study discusses a method of creating 
a hollow microcapsule through using a biodegradable core and later degrading it, thus 
providing a hollow microcapsule which could be loaded with the desired drugs. 
 
The other main future objective was to use a new mechanism to elute the drugs from the 
capsules once they are coated on to the stents. The mechanism to be used would be ideally 
something that could control the drug release. One of the potential mechanisms that was 
found when exploring through research was the use of ultrasound. But research in this 
area should deal with the conditions which would be required to make such a system 
possible. High frequency ultrasound with lower power has been used widely in medicine 
[12]. Therefore, there has been interest in this area of using this kind of an ultrasound 
based stimulus to break the drug carrier to enable drug release. 
 
But future research should focus on the various parameters which need to be tweaked to 
make sure that the external stimuli which might be used to trigger the drug release does 
not lead to any side effects. Therefore, the safety aspect of the system needs to be 
extensively researched before trials and potential implementation. It is also necessary to 
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have trials with real drugs in place of Rh6G to find out the efficacy of the system in a real 
world scenario. Though there has been a lot of research work on treating CVDs till date, 
there are only few reports which deal with novel drug delivery systems such as this. Of 
the few that are available, some studies have even opened up some negative possibilities 
on the use of certain stimuli like ultrasound, which may lead to certain undesired effects 
on the heart like irregular rhythm [103]. Some of the studies have not taken many 
clinically relevant conditions into account while performing the study and this further 
complicates the data that have been obtained. Therefore, this area of medicine is still in 
its early stages and needs a lot of research for development and attaining clinically usable 
systems. 
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7.Conclusion 
 
This thesis began with an aim to create an entity which would aid in the development of 
current drug delivery systems. The entity being the microcapsules and the drug delivery 
system being the DESs. The project was successful in synthesising the microcapsules 
through assembly of the various nano-components which were synthesised separately. It 
is very much hoped that the efficacy of the synthesised microcapsules for coating on stents 
could be studied in future research and also the potential to elute the drugs by means of 
ultrasound or other novel stimuli which would help one control the drug release could be 
explored. If future research succeeds in coating the said nanoparticles onto stents and 
eluting it by means of ultrasound for example, systemic drug delivery for ISR could 
become obsolete in the future. And although implants in the human body can be traced 
back to ancient times, coronary stents have been used only since the 1990s, and still they 
have not been yet made in such a way that they do not trigger any response form the human 
body. With increasing number of younger patients with CHDs who are receiving stent 
implants, the need for the treatment of stent related conditions such as ISR and late stent 
thrombosis remains highly essential, therefore stents which are coated with these 
microcapsules and which could remain with the stents as the patient ages could be of 
immense use, especially the possibility to elute the drugs at a later age of the patient 
avoiding the need to do an invasive procedure. Therefore, this project needs to proceed in 
that direction of the creation of a newer and far more advanced drug delivery system, 
which could lead to the development of better targeted drug delivery treatments which 
employ controlled drug deliveries for CHDs, and also advanced and better stents. 
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